Seaport Therapeutics' stock soared 25.72% intraday on Friday, marking a strong debut for the biotechnology company.
The surge follows the company's initial public offering, which was priced at $18 per share at the top of the targeted range. The IPO was upsized to 14.2 million shares from 11.8 million shares, reflecting robust investor interest. The offering is expected to generate approximately $254.9 million in gross proceeds for the company.
Seaport Therapeutics' stock began trading on the Nasdaq Global Select Market under the ticker SPTX, with the opening price significantly above the IPO price, driving the substantial intraday gain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.